Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Azacitidine in Newly Diagnosed T-ALL
NCT05376111Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Apr 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in t-cell acute lymphoblastic leukemia (T-ALL), sponsored by First Affiliated Hospital of Soochow University. Started Apr 2022; status: recruiting.
02
Drugs
venetoclax
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT05376111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05376111.